Journal of Hepatology
Volume 39, Issue 2 , Pages 222-230 , August 2003

Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B

  • Robert P. Myers

      Affiliations

    • Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
    • Current address: Liver Unit, University of Calgary, Calgary, Alberta, Canada.
    • ,
  • Marie-Hélène Tainturier

      Affiliations

    • Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
    • ,
  • Vlad Ratziu

      Affiliations

    • Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
    • ,
  • Annie Piton

      Affiliations

    • Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
    • ,
  • Vincent Thibault

      Affiliations

    • Department of Virology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
    • ,
  • Françoise Imbert-Bismut

      Affiliations

    • Department of Biochemistry, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
    • ,
  • Djamila Messous

      Affiliations

    • Department of Biochemistry, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
    • ,
  • Frederic Charlotte

      Affiliations

    • Department of Pathology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
    • ,
  • Vincent Di Martino

      Affiliations

    • Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
    • ,
  • Yves Benhamou

      Affiliations

    • Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
    • ,
  • Thierry Poynard

      Affiliations

    • Department of Hepatology and Gastroenterology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
    • Corresponding Author InformationCorresponding author. Groupe Hospitalier Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France. Tel.: +33-1-42-16-10-02; fax: +33-1-42-16-14-27

Received 2 December 2002 ,Revised 21 March 2003 ,Accepted 27 March 2003.

References 

  1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745
  2. McMahon BJ. Hepatocellular carcinoma and viral hepatitis. In:  Wilson RA editors. Viral hepatitis. New York, NY: Marcel Dekker; 1997;p. 315–330
  3. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al.  Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991;32:294–298
  4. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8:493–496
  5. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al.  Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol. 1997;145:1039–1047
  6. Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, et al.  Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med. 1984;101:613–616
  7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225–1241
  8. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology. 1999;30:770–774
  9. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology. 1990;99:1396–1400
  10. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, et al.  Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986;1:523–525
  11. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al.  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614–2618
  12. Friedman SL, Maher JJ, Bissell DM. Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology. 2000;32:1403–1408
  13. ter Borg F, ten Kate FJ, Cuypers HT, Leentvaar-Kuijpers A, Oosting J, Wertheim-van Dillen PM, et al.  Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen. Lancet. 1998;351:1914–1918
  14. Zavaglia C, Mondazzi L, Maggi G, Iamoni G, Gelosa F, Bellati G, et al.  Are alanine aminotransferase, hepatitis B virus DNA or IgM antibody to hepatitis B core antigen serum levels predictors of histological grading in chronic hepatitis B?. Liver. 1997;17:83–87
  15. Giustina G, Fattovich G, De Paoli M, Guido M, Favarato S, Rugge M, et al.  Serum procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and response to interferon-alpha therapy. Int J Clin Lab Res. 1996;26:33–36
  16. Pontinha N, Pessegueiro H, Barros H. Serum hyaluronan as a marker of liver fibrosis in asymptomatic chronic viral hepatitis B. Scand J Clin Lab Invest. 1999;59:343–347
  17. Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol. 1999;14:138–145
  18. Murawaki Y, Nishimura Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Plasma transforming growth factor-beta 1 concentrations in patients with chronic viral hepatitis. J Gastroenterol Hepatol. 1998;13:680–684
  19. Ding H, Chen Y, Feng X, Liu D, Wu A, Zhang L. Correlation between liver fibrosis stage and serum liver fibrosis markers in patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2001;9:78–80
  20. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069–1075
  21. Myers RP, Benhamou Y, Bochet M, Imbert-Bismut F, Thibault V, Ratziu V, et al.  Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients. AIDS. 2003;17:721–725
  22. Myers RP, Messous D, Thabut D, Imbert-Bismut F, Ratziu V, Mercadier A, et al.  The prediction of fibrosis with serum biochemical markers in patients with chronic hepatitis C: prospective validation in 534 patients (abstract). Hepatology. 2002;36:351A
  23. Myers RP, Messous D, Thabut D, Imbert-Bismut F, Ratziu V, Mercadier A, et al.  Life is possible without biopsy in patients with chronic hepatitis C: validation of biochemical markers of liver fibrosis and activity in 1570 patients and blood donors (abstract). Hepatology. 2002;36:351A
  24. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated interferon alfa-2b and ribavirin combination (abstract). Hepatology. 2002;36:351A
  25. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al.  Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. The GERMED cyt-04 group. J Viral Hepat. 2002;9:128–133
  26. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–293
  27. Bergmeyer HU, Horder M, Rej R. International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (l-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2). J Clin Chem Clin Biochem. 1986;24:481–495
  28. Bergmeyer HU, Horder M, Rej R. International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 2. IFCC method for aspartate aminotransferase (l-aspartate: 2-oxoglutarate aminotransferase, EC 2.6.1.1). J Clin Chem Clin Biochem. 1986;24:497–510
  29. Persijn JP, van der Slik W. A new method for the determination of gamma-glutamyltransferase in serum. J Clin Chem Clin Biochem. 1976;14:421–427
  30. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839–843
  31. de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, et al.  The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993;118:191–194
  32. Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology. 1987;7:302–306
  33. Franck PF, Steen G, Lombarts AJ, Souverijn JH, van Wermeskerken RK. Multicenter harmonization of common enzyme results by fresh patient-pool sera. Clin Chem. 1998;44:614–621
  34. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, et al.  A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol. 2002;2:3
  35. Arico S, Aragona M, Rizzetto M, Caredda F, Zanetti A, Marinucci G, et al.  Clinical significance of antibody to the hepatitis delta virus in symptomless HBsAg carriers. Lancet. 1985;2:356–358
  36. Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci. 1994;39:2426–2432
  37. Kawser CA, Iredale JP, Winwood PJ, Arthur MJ. Rat hepatic stellate cell expression of alpha2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci (Colch). 1998;95:179–186
  38. Poynard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, et al.  A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology. 1991;100:1397–1402
  39. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, et al.  Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol. 1998;28:439–442
  40. Paradis V, Mathurin P, Ratziu V, Poynard T, Bedossa P. Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix. Hepatology. 1996;23:1232–1238
  41. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, et al.  TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol. 1999;276:G1059–GF1068

PII: S0168-8278(03)00171-5

doi: 10.1016/S0168-8278(03)00171-5

Journal of Hepatology
Volume 39, Issue 2 , Pages 222-230 , August 2003

Article Tools

* Image Usage & Resolution